CANTA Share Price Performance
SEK 0
-1.24 (-100.00%)
Price SEK 0
Fair ValueSEK 10.50
Share Pricen/a
Narrative Update • Jul 01
Cantargia AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
CANTA Community Narratives
AN
Fair Value
·Fair Value SEK 10.5 81.0% undervalued intrinsic discount
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value SEK 6 66.7% undervalued intrinsic discount
IL1RAP Platform Risks And Shifting Cancer Standards Will Eventually Reveal Hidden Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 14 85.7% undervalued intrinsic discount
IL1RAP Platform Will Unlock Long Term Value Through PDAC And Autoimmune Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
IL1RAP Platform Risks And Shifting Cancer Standards Will Eventually Reveal Hidden Upside
Cantargia’s cancer drug efforts sit in the middle of a fast-changing treatment landscape, where new combo approaches could either unlock a clear place for its IL1RAP platform or make it harder to stand out. At the same time, promising early results in a blood cancer study and a big-pharma partnership hint at upside—if the company can fund and execute its trials without long delays or heavy dilution.Read more
AN
SEK 6
66.7% undervalued intrinsic discount
Fair Value
Revenue
-14.58% p.a.
Profit Margin
19.65%
Future PE
44.89x
Price in 2029
SEK 7.01
IL1RAP Platform Will Unlock Long Term Value Through PDAC And Autoimmune Expansion
Catalysts About Cantargia Cantargia is a clinical stage biotech company developing IL1RAP targeted antibody therapies for oncology and inflammatory or autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 14
85.7% undervalued intrinsic discount
Fair Value
Revenue
-65.9% p.a.
Profit Margin
18.02%
Future PE
2.25kx
Price in 2028
SEK 9.07
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
Catalysts About Cantargia Cantargia is a biotech company developing IL1RAP targeted antibodies for oncology and inflammatory or autoimmune diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
SEK 10.5
81.0% undervalued intrinsic discount
Fair Value
Revenue
-69.02% p.a.
Profit Margin
17.99%
Future PE
2.25kx
Price in 2028
SEK 6.8
Trending Discussion
Recently Updated Narratives
AN
CANTA: Recent Equity Raises Will Support Advancing High-Risk MDS And AML Trial
Fair Value: SEK 6 66.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IL1RAP Platform Will Unlock Long Term Value Through PDAC And Autoimmune Expansion
Fair Value: SEK 14 85.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
IL1RAP Platform Advancements And Strong Cash Runway Will Support Long Term Biotech Upside
Fair Value: SEK 10.5 81.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cantargia AB (publ) Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 19, 2026
- 0.65
- 100.00%
- 50.73%
- 0%
About CANTA
- Founded
- 2009
- Employees
- 22
- CEO
- WebsiteView website
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform. The company has collaboration agreements with Otsuka Pharmaceutical Co., Ltd for the clinical IL1RAP targeting antibody CAN10 as well as the preclinical antibody 3G5; and BioWa Inc., granted a nonexclusive license to use the technology platform POTELLIGENT® for the manufacture of the drug candidate nadunolimab. Cantargia AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
